These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32508971)

  • 1. EZH2-inhibitor DZNep enhances apoptosis of renal tubular epithelial cells in presence and absence of cisplatin.
    Chen SQ; Li JQ; Wang XQ; Lei WJ; Li H; Wan J; Hu Z; Zou YW; Wu XY; Niu HX
    Cell Div; 2020; 15():8. PubMed ID: 32508971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression.
    Ni J; Hou X; Wang X; Shi Y; Xu L; Zheng X; Liu N; Qiu A; Zhuang S
    Cell Death Dis; 2019 May; 10(5):355. PubMed ID: 31043583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
    Girard N; Bazille C; Lhuissier E; Benateau H; Llombart-Bosch A; Boumediene K; Bauge C
    PLoS One; 2014; 9(5):e98176. PubMed ID: 24852755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High glucose-stimulated enhancer of zeste homolog-2 (EZH2) forces suppression of deptor to cause glomerular mesangial cell pathology.
    Das F; Bera A; Ghosh-Choudhury N; Sataranatarajan K; Kamat A; Kasinath BS; Choudhury GG
    Cell Signal; 2021 Oct; 86():110072. PubMed ID: 34224844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting histone methyltransferase enhancer of zeste homolog-2 inhibits renal epithelial-mesenchymal transition and attenuates renal fibrosis.
    Zhou X; Xiong C; Tolbert E; Zhao TC; Bayliss G; Zhuang S
    FASEB J; 2018 May; 32(11):fj201800237R. PubMed ID: 29775417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression.
    Zhou X; Zang X; Ponnusamy M; Masucci MV; Tolbert E; Gong R; Zhao TC; Liu N; Bayliss G; Dworkin LD; Zhuang S
    J Am Soc Nephrol; 2016 Jul; 27(7):2092-108. PubMed ID: 26701983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of EZH2 ameliorates hyperoxaluria-induced kidney injury through the JNK/FoxO3a pathway.
    Gao X; Peng Y; Fang Z; Li L; Ming S; Dong H; Li R; Zhu Y; Zhang W; Zhu B; Liao J; Wang Z; Liu M; Li W; Zeng J; Gao X
    Life Sci; 2022 Feb; 291():120258. PubMed ID: 34952043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting enhancer of zeste homolog 2 protects against acute kidney injury.
    Zhou X; Zang X; Guan Y; Tolbert T; Zhao TC; Bayliss G; Zhuang S
    Cell Death Dis; 2018 Oct; 9(11):1067. PubMed ID: 30341286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
    Lee JK; Kim KC
    Biochem Biophys Res Commun; 2013 Sep; 438(4):647-52. PubMed ID: 23933322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
    Cai L; Wang Z; Liu D
    Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia.
    Shi Y; Xu L; Tao M; Fang L; Lu J; Gu H; Ma S; Lin T; Wang Y; Bao W; Qiu A; Zhuang S; Liu N
    Am J Physiol Renal Physiol; 2019 Mar; 316(3):F488-F505. PubMed ID: 30566000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective EZH2 inhibitor zld1039 alleviates inflammation in cisplatin-induced acute kidney injury partially by enhancing RKIP and suppressing NF-κB p65 pathway.
    Wen L; Tao SH; Guo F; Li LZ; Yang HL; Liang Y; Zhang LD; Ma L; Fu P
    Acta Pharmacol Sin; 2022 Aug; 43(8):2067-2080. PubMed ID: 34937916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
    Au SL; Wong CC; Lee JM; Wong CM; Ng IO
    PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancer of zeste homolog 2 modulates oxidative stress-mediated pyroptosis in vitro and in a mouse kidney ischemia-reperfusion injury model.
    Liu H; Chen Z; Weng X; Chen H; Du Y; Diao C; Liu X; Wang L
    FASEB J; 2020 Jan; 34(1):835-852. PubMed ID: 31914694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis.
    Jiang Y; Xiang C; Zhong F; Zhang Y; Wang L; Zhao Y; Wang J; Ding C; Jin L; He F; Wang H
    Theranostics; 2021; 11(1):361-378. PubMed ID: 33391480
    [No Abstract]   [Full Text] [Related]  

  • 17. Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model.
    Akpa CA; Kleo K; Oker E; Tomaszewski N; Messerschmidt C; López C; Wagener R; Oehl-Huber K; Dettmer K; Schoeler A; Lenze D; Oefner PJ; Beule D; Siebert R; Capper D; Dimitrova L; Hummel M
    BMC Cancer; 2020 May; 20(1):427. PubMed ID: 32408898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone H3K27 methyltransferase EZH2 regulates apoptotic and inflammatory responses in sepsis-induced AKI.
    Li B; Xia Y; Mei S; Ye Z; Song B; Yan X; Lin F; Rao T; Yu W; Mei C; Lv J; Wu M; Mao Z; Zhou X; Cheng F
    Theranostics; 2023; 13(6):1860-1875. PubMed ID: 37064878
    [No Abstract]   [Full Text] [Related]  

  • 19. DZNep promotes mouse bone defect healing via enhancing both osteogenesis and osteoclastogenesis.
    Cao X; He W; Rong K; Xu S; Chen Z; Liang Y; Han S; Zhou Y; Yang X; Ma H; Qin A; Zhao J
    Stem Cell Res Ther; 2021 Dec; 12(1):605. PubMed ID: 34930462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation.
    Fujiwara T; Saitoh H; Inoue A; Kobayashi M; Okitsu Y; Katsuoka Y; Fukuhara N; Onishi Y; Ishizawa K; Ichinohasama R; Harigae H
    J Biol Chem; 2014 Mar; 289(12):8121-34. PubMed ID: 24492606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.